New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
Ventyx Biosciences combines clinical stage programs of three companies co-founded and merged by New Science Ventures
News provided by
Share this article
Share this article
NEW YORK and LONDON, March 9, 2021 /PRNewswire/ New Science Ventures LLC ( NSV ), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs.
Ventyx Biosciences combines assets from three formerly independent, asset-centric companies – Oppilan Pharma (targeting S1P1R), Zomagen Biosciences (targeting the NLRP3 inflammasome) and the original Ventyx Biosciences (targeting TYK2) – which were founded and merged by Raju Mohan, CEO of Ventyx Biosciences, and New Science Ventures.
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
solar
Daniel Graña, emerging market equities portfolio manager at Janus Henderson Investors, Matt Doody, emerging market equities analyst, and Jennifer James, emerging market credit portfolio manager, discuss how Chinaâs decarbonisation has the potential to be one of the next major investment themes.
At the 2020 United Nations General Assembly, Chinese president Xi Jinping caught the worldâs attention when he stated that his country would target peak carbon emissions in 2030 and seek to achieve carbon neutrality by 2060.
Considering that China, home to the second-largest economy in the world, is the worldâs largest carbon emitter and president Xiâs targets are more ambitious than those of other industrialised countries, this initiative has the potential to reframe the global debate on whatâs possible when addressing climate change.
Is China s carbon clampdown the next investing mega-theme? cmcmarkets.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cmcmarkets.com Daily Mail and Mail on Sunday newspapers.
Share
The 2020s are on course to become the decade of the special purpose acquisition companies (SPACs), also known as blank check or shell companies. SPACs are set to outpace IPOs once again in 2021, after a record year that saw SPACs mature from a once obscure method of going public to a rabid, flavor-of-the-month frenzy amidst both institutional and retail investors.
The year of COVID-19 saw 227 SPACs top traditional IPOs for the first time in history, raising $76 billion, compared to 67 billion raised from traditional IPOs. The first two months of 2021 have so far generated 144 SPACs, raising $44 billion. Digital Health has certainly ridden the recent SPAC wave, with yet a few more splashes yet to come.